First-Line Management of Central Serous Retinopathy
For acute central serous chorioretinopathy (CSC) presenting within the first 2-4 months, observation is the first-line management, as spontaneous resolution occurs in the majority of cases. 1
Management Algorithm by Disease Stage
Acute CSC (Symptoms < 2-4 months)
Observation for 4-6 months is the standard approach unless specific circumstances warrant earlier intervention 1. The 2024 evidence-based guideline from Progress in Retinal and Eye Research clearly establishes this as first-line management given the high rate of spontaneous subretinal fluid (SRF) resolution 1.
Immediate treatment should be considered if:
- Patient is highly symptomatic and requires rapid visual rehabilitation (e.g., professional pilots, surgeons)
- Recurrent episode
- Bilateral disease activity
- Patient preference for treatment after informed discussion 1
When immediate treatment is chosen, ICGA- and FA-guided half-dose (or half-fluence) photodynamic therapy (PDT) is the preferred intervention 1. This targets hyperfluorescent areas on indocyanine green angiography that correspond to focal leakage on fluorescein angiography and SRF on OCT.
Chronic CSC (Persistent SRF > 4-6 months)
ICGA- and FA-guided half-dose (or half-fluence) PDT is the first-line treatment for chronic CSC 1. This represents the strongest evidence-based recommendation from the 2024 guideline 1.
The PLACE trial demonstrated clear superiority of half-dose PDT over micropulse laser, with 67% versus 29% achieving complete SRF resolution at 7-8 months, along with significantly better visual acuity and retinal sensitivity improvements 1.
Alternative options when PDT is unavailable:
- Focal laser photocoagulation for extrafoveal leakage points only (outside central macula) 1
- This carries risks including paracentral scotoma, macular neovascularization, and chorioretinal adhesions 1
Critical Management Considerations
Before any treatment, discuss cessation of corticosteroids if currently in use 1. This is a crucial first step often overlooked.
Observation is not benign: While acute CSC often resolves spontaneously, retinal damage can occur during the early phases. Residual SRF—even when shallow and undetectable on slit-lamp examination—can lead to photoreceptor and RPE atrophy with vision loss over years 1. OCT imaging is therefore critical for diagnosis and monitoring.
What NOT to Use as First-Line
Mineralocorticoid receptor antagonists (eplerenone, spironolactone) showed poor efficacy in large RCTs. The SPECTRA and VICI trials found only 16-17% complete SRF resolution at 15 months with eplerenone, similar to placebo 1. These should not be considered first-line despite earlier retrospective studies suggesting benefit.
Micropulse laser has modest evidence of efficacy and is inferior to PDT 1. It may be attempted when PDT is unavailable and focal laser is not feasible, but expectations should be tempered.
Common Pitfalls to Avoid
- Don't wait indefinitely in acute cases: The traditional "wait 4 months" recommendation lacks strong objective evidence and fails to account for ongoing photoreceptor damage 1
- Don't use full-dose PDT: Half-dose or half-fluence PDT is equally effective with better safety profile 2
- Don't attempt focal laser near the fovea: Risk of permanent scotoma outweighs benefits 1
- Don't miss neovascularization: Always obtain OCT-A, FA, and ICGA if SRF persists after treatment to rule out macular neovascularization requiring anti-VEGF therapy 1
Monitoring Strategy
For observed acute cases, perform OCT at 1-3 month intervals. If only minimal residual SRF remains, conservative follow-up is reasonable. However, if SRF persists or increases at 4-6 months, proceed with treatment per chronic CSC pathway 1.